AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 291: F67-F78, 2006. First published February 14, 2006; doi:10.1152/ajprenal.00412.2005
0363-6127/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/1/F67    most recent
00412.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, H. T.
Right arrow Articles by Emala, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, H. T.
Right arrow Articles by Emala, C. W.

Anti-inflammatory and antinecrotic effects of the volatile anesthetic sevoflurane in kidney proximal tubule cells

H. Thomas Lee, Mihwa Kim, Michael Jan, and Charles W. Emala

Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York

Submitted 19 October 2005 ; accepted in final form 7 February 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Renal ischemia-reperfusion (IR) injury is a major clinical problem without effective therapy. We recently reported that volatile anesthetics protect against renal IR injury, in part, via their anti-inflammatory properties. In this study, we demonstrate the anti-inflammatory and antinecrotic effects of sevoflurane in cultured kidney proximal tubule cells and probed the mechanisms of sevoflurane-induced renal cellular protection. To mimic inflammation, human kidney proximal tubule (HK-2) cells were treated with tumor necrosis factor-{alpha} (TNF-{alpha}; 25 ng/ml) in the presence or absence of sevoflurane. In addition, we studied the effects of sevoflurane pretreatment on hydrogen peroxide (H2O2)-induced necrotic cell death in HK-2 or porcine proximal tubule (LLC-PK1) cells. We demonstrate that sevoflurane suppressed proinflammatory effects of TNF-{alpha} evidenced by attenuated upregulation of proinflammatory cytokine mRNA (TNF-{alpha}, MCP-1) and ICAM-1 protein and reduced nuclear translocation of the proinflammatory transcription factors NF-{kappa}B and AP-1. Sevoflurane reduced necrotic cell death induced with H2O2 in HK-2 cells as well as in LLC-PK1 cells. Sevoflurane treatment resulted in phosphorylation of prosurvival kinases, ERK and Akt, and increased de novo HSP-70 protein synthesis without affecting the synthesis of HSP-27 or HSP-32. We conclude that sevoflurane has direct anti-inflammatory and antinecrotic effects in vitro in a renal cell type particularly sensitive to injury following IR injury. These mechanisms may, in part, account for volatile anesthetics' protective effects against renal IR injury.

acute renal failure; HK-2 cells; inflammation; necrosis; perioperative period

THE RISK OF ACUTE RENAL FAILURE following intraoperative renal ischemia and reperfusion (IR) is significantly increased in patients with impaired preoperative renal function (33), and the onset of acute renal failure is associated with increased mortality and morbidity (1, 54). Unfortunately, the prognosis of acute renal failure in the perioperative period has changed little for the last 40 years (32, 37). The vast majority of patients undergoing surgery are exposed to volatile anesthetics such as sevoflurane during the intraoperative period. We recently demonstrated that volatile anesthetics have protective effects against renal IR injury in rats (29). This in vivo protection was associated with significantly less necrosis, better preservation of renal tubular architecture as well as reduced inflammation, and reduced neutrophil influx into the kidney. However, it is unclear whether volatile anesthetics reduce necrosis and inflammation of the kidney via direct protective effects on renal tubule cells and/or via indirect effects (e.g., via reducing proinflammatory leukocyte influx and attenuating inflammation caused by these cells). Specifically, it is not known whether volatile anesthetics have direct antinecrotic and/or direct anti-inflammatory effects in vitro in cultured proximal tubule cells. Moreover, the renal cell type potentially protected by volatile anesthetics is not known.

We aimed to determine whether volatile anesthetics directly reduce oxidant-induced necrosis (induced with H2O2) and inflammation (induced with TNF-{alpha} and H2O2) in vitro. We studied sevoflurane [2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether] as a representative volatile anesthetic as this anesthetic is a widely used inhalational anesthetic in the US. We used cultures of human renal proximal tubules (HK-2 cells) as this is the renal cell type most susceptible to necrosis after renal IR injury (30, 51). We also utilized a cultured pig kidney cell line typical of normal kidney tubular epithelium (LLC-PK1) to confirm the antinecrotic renal effects of sevoflurane in another proximal tubule cell type. We hypothesized that as we demonstrated in vivo, sevoflurane treatment would protect against oxidant-mediated necrotic injury as well as reduce inflammation in renal tubular cells. In addition, we also aimed to determine the signaling pathways of sevoflurane-mediated protection against oxidant injury in renal proximal tubular cells. Increased cell survival after IR injury has been demonstrated via activation of prosurvival kinases (ERK and Akt) as well as by increased synthesis of heat shock proteins (e.g., HSP-70) which act as cellular chaperones to protect against injury. Among members of the HSP family, HSP-27, -32 (also known as heme oxygenase-1), and -70 are well-known protectants against renal IR injury (31, 43, 66). Therefore, we determined whether sevoflurane activated ERK and Akt and tested the ability of sevoflurane to upregulate the expression of heat shock proteins (HSP-27, -32, or -70) in renal tubular cells.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cell culture. HK-2 and LLC-PK1 cells (immortalized human proximal tubule and porcine renal tubular cell lines, respectively; American Type Culture Collection, Manassas, VA) were grown and passaged in culture medium (keratinocyte serum-free medium plus 5 ng/ml epidermal growth factor and 40 mg/ml bovine pituitary extract for HK-2 cells and medium 199 plus 5% serum for LLC-PK1 cells) and antibiotics (100 U/ml of penicillin G, 100 µg/ml of streptomycin, and 0.25 µg/ml of amphotericin B) at 37°C in a 100% humidified atmosphere of 5% CO2-95% air. These cell lines have been characterized extensively and retain the phenotypic and functional characteristics of proximal tubule cells in culture (16, 51). They were plated in 6- or 24-well plates when 80% confluent and used in the experiments described below when confluent.

Exposure of cultured renal tubule cells to sevoflurane. For sevoflurane treatment, HK-2 cells were placed in an air-tight, 37°C, humidified modular incubator chamber (Billups-Rothenberg, Del Mar, CA) with inflow and outflow connectors. The inlet port was connected to the in-line agent-specific calibrated sevoflurane vaporizer (Datex-Ohmeda) to deliver sevoflurane [0.55–4.4% or 0.25–2 minimum alveolar concentration (MAC)] mixed with 95% air-5% CO2 at 10 l/min. The outlet port was connected to a Datex-Ohmeda 5250 RGM gas analyzer that measured sevoflurane concentrations. Exposure to sevoflurane lasted 1–16 h. Control cells were exposed to 95% air-5% CO2 in a modular incubator chamber.

Induction of proximal tubule cell necrosis with H2O2. After indicated pretreatment with or without 2.2% (1 MAC) sevoflurane (1–16 h), confluent monolayers of HK-2 or LLC-PK1 proximal tubule cells grown in 6- or 24-well plates were treated with 1–5 mM H2O2 for 2–8 h at 37°C in a 95% air-5% CO2 incubator. We demonstrated previously that H2O2-induced necrosis in HK-2 or LLC-PK1 cells is dose and time dependent (26). We chose to utilize 1–5 mM H2O2 as published experiments demonstrated that these doses killed renal tubular cells rapidly (~70% total LDH released within 1 h). Lower doses (~0.5–2 mM) killed cells more slowly (3–16 h). The doses we proposed are comparable to those employed previously in both the characterization of this cell line and in its validation as a cell culture model of oxidant injury (51).

To determine whether inhibition of Akt or ERK reduced or prevented sevoflurane-mediated proximal tubule protection, an inhibitor of MEK1 (50 µM PD-98059 for 30 min) or phosphatidylinositol 3-kinase (PI3K) (100 nM wortmannin for 30 min) was added before 16-h sevoflurane treatment. Some cells were treated with inhibitors of signaling intermediates only (no sevoflurane or H2O2) to determine the effects of these inhibitors on cell survival. To determine whether inhibition of ERK or Akt at the time of H2O2 injury (after 16-h sevoflurane pretreatment) prevented sevoflurane-mediated proximal tubule protection, some cells were treated with an inhibitor of MEK1 or PI3K after sevoflurane treatment but before H2O2 injury. The doses of inhibitors were determined in preliminary experiments to selectively block MEK1 or PI3K by preventing ERK1/2 or Akt phosphorylation, respectively. Our preliminary studies indicate that our treatment protocols with TNF-{alpha} and H2O2 cause negligible apoptosis (data not shown).

Induction of proximal tubule cell inflammation with TNF-{alpha} and H2O2. In addition to oxidant stress, TNF-{alpha} has been implicated in initiating an inflammatory process after acute renal failure (47, 48). We therefore used TNF-{alpha} and H2O2 to mimic an inflammatory process occurring in vivo after renal IR injury. Confluent monolayers of HK-2 cells were treated with 10 ng/ml recombinant TNF-{alpha} (Calbiochem) or 100–500 µM H2O2 and exposed to 2.2% sevoflurane or air plus 5% CO2 in a modular incubator chamber for 2–16 h. The dose of TNF-{alpha} was determined in preliminary experiments to produce consistent inflammatory changes in renal tubular cells (data not shown).

Measurement of cell viability with LDH. LDH released into cell culture media as indexes of cell death was measured using an LDH assay kit from Promega (Madison, WI). LDH released into the media was expressed as the percentage of total cellular LDH per well measured after the cells were lysed with 1% Triton X-100.

Immunoblot analyses. We measured the activation (via phosphorylation) of extracellular signal-regulated protein kinase (ERK) mitogen-activated protein kianse (MAPK) and Akt (protein kinase B, PKB) by immunoblotting after treatments with 2.2% sevoflurane. Phospho-ERK and phospho-Akt blots were stripped and reprobed for total ERK and Akt. The densitometric quantification was expressed as a ratio of phosphorylated over total forms. We also measured expression of ICAM-1 protein in HK-2 cells after TNF-{alpha} or H2O2 treatment and the modulation of ICAM-1 protein expression following sevoflurane exposure. Immunoblotting was performed as described previously (26, 28). In brief, the HK-2 cells in six-well plates were washed twice with Hank's balanced salt solution (HBSS) and scraped with 100 µl of calcium-free HBSS plus protease inhibitors (2 µg/ml leupeptin and 2 µg/ml aprotinin). Aliquots were used for protein assay and the remainders were mixed with an equal volume of sample buffer (62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol, and 5% beta-mercaptoethanol, final concentration). Twenty to forty micrograms of each sample were electrophoresed at room temperature through discontinuous 10% SDS-polyacrylamide gels at 80 V for 4 h and subjected to immunoblot analysis. The primary antibodies for phospho-ERK1/2, HSP-27, HO-1 (HSP-32), and ICAM-1 were from Santa Cruz Biotechnology. Antibodies for phospho-Akt and HSP-27 were from Cell Signaling Technologies. The antibody for the inducible form of HSP-70 was from Stressgen Biotechnologies. The secondary antibody (goat anti-rabbit or anti-mouse IgG conjugated to horseradish peroxidase at 1:5,000 dilution) was detected with enhanced chemiluminescence immunoblotting detection reagents (Amersham), with subsequent exposure to a CCD camera coupled to a UVP Bioimaging System (Upland, CA) and a personal computer. The band intensities of the immunoblots were within the linear range of exposure for all experiments.

Semiquantitative RT-PCR for proinflammatory cytokines. RNA from HK-2 cells was extracted and RT-PCR reactions for proinflammatory mRNAs and HSPs (HSP-27, HO-1, HSP-70) were performed with the one-step RT-PCR kit as described previously (Access RT-PCR System, Promega) (29). The quantitative accuracy of our RT-PCR technique was first confirmed for each primer pair used. The PCR cycle number for each primer pair was optimized for linear increases in densitometric band intensity measurements with increasing PCR cycles from 14–22. The starting amount of RNA (0.25–1 µg) was also optimized for linear increase in densitometric band intensity measurements at an optimized cycle of PCR. We used primers designed to recognize human sequences based on sequences of proinflammatory genes (Table 1; Sigma Genosys, Woodlands, TX). They were chosen to yield expected PCR products of 200 to 600 bp, have a 50–60% GC content, and all span an intron to distinguish mRNA products from genomic DNA contamination. Five microliters of the RT-PCR product were analyzed on a 6% acrylamide gel stained with SYBR green (Invitrogen, Carlsbad, CA) for analysis with a UVP Bioimaging System. Semiquantitative analysis of mRNA expression gene was accomplished by obtaining the ratio of the band density of the mRNA's of interest to that of GAPDH (a housekeeping gene) from the same sample.


View this table:
[in this window]
[in a new window]
  		Table 1. Primer sequences

 
Nuclear protein extraction. HK-2 cells were scraped in 500 µl of buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 20% glycerol, 0.2 mM PMSF, 0.5 mM DTT; Protease Inhibitor Cocktail, Roche, Indianapolis, IN) for 10 min at 4°C. The cells were homogenized using a polytron homogenizer for 5 s to release the nuclei into solution and centrifuged at 18,000 g for 5 min at 4°C. The supernatant was discarded and the pellet was resuspended in 50 µl of buffer B (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.5 mM EDTA, 25% glycerol, 0.1% Triton X-100, 0.2 mM PMSF, 0.5 mM DTT; Protease Inhibitor Cocktail) and incubated for 1 h at 4°C with occasional swirling to extract nuclear protein. The solubilized pellet was centrifuged at 16,000 g for 15 min and the supernatant containing nuclear proteins was used for EMSAs.

EMSA. EMSA was performed using the Gel Shift Assay Systems (Promega). The oligonucleotides for NF-{kappa}B and AP-1 (Promega) consensus sequences were end-labeled with 10 µCi of {gamma}32P ATP (Perkin Elmer Life Technology) and purified using a G-25 Spin Column (Amersham Biosciences). Ten micrograms of the nuclear extract were incubated with 1 µl of the labeled probe for 20 min at room temperature and electrophoresed on a 4% polyacrylamide gel (200 V at 4°C). Two micrograms of Hela nuclear extract (Promega) were used for positive control and 1 µl of a TransCruz polyclonal antibody for p65 subunit of NF-{kappa}B or antibody for c-fos (for AP-1; Santa Cruz Biotechnology) was coincubated with the nuclear protein and probe for a supershift reaction. One hundred-fold concentration of cold probe was coincubated as a competitor for a negative control reaction. The gel was then transferred to a blotting paper and exposed to X-ray film or scanned with a PhosphoImager (Molecular Dynamics) for radioactive band intensity analysis.

Protein determination. Protein content was determined with the Pierce Chemical (Rockford, IL) bicinchoninic acid protein assay reagent with bovine serum albumin as a standard.

Statistical analysis. The data were analyzed with Student's t-test when comparing means between two groups or with one-way ANOVA plus Tukey's post hoc multiple comparison test to compare mean values across multiple treatment groups. In all cases, a probability statistic <0.05 was taken to indicate significance. All data are expressed throughout the text as means ± SE.

Materials. All drugs were in saline. Otherwise specified, all chemicals were obtained from Sigma (St. Louis, MO).


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Sevoflurane reduces necrosis in HK-2 cells. HK-2 or LLC-PK1 cells pretreated with sevoflurane (0.55–4.4% or 0.25–2 MAC) released significantly less LDH following 5 mM H2O2 treatment compared with control cells exposed to 95% air-5% CO2 for 16 h (Fig. 1, A and B). Specifically, HK2 cells treated for 8 h with 5 mM H2O2 released 25.2 ± 2.3% of total cellular LDH which was reduced to 18.1 ± 2.1% by 16 h of 2.2% sevoflurane pretreatment (n = 6, P < 0.05; Fig. 1A). Likewise, following 8 h of 5 mM H2O2, LLC-PK1 cells released 52.5 ± 2.0% of total cellular LDH which was reduced to 36.6 ± 0.8% in cells pretreated with 16 h of 2.2% (1 MAC) sevoflurane (n = 9, P < 0.05; Fig. 1B).


Figure 1
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 1. LDH release after H2O2 injury in HK-2 cells (A; n = 6) and LLC-PK1 cells (B, C, D; n = 9) with or without sevoflurane (Sevo) pretreatment (2.2% for 16 h). Released LDH from cells was expressed as a percentage of total LDH (LDH released plus intracellular LDH). A: LDH release in HK-2 cells pretreated with 2.2% sevoflurane/air + 5% CO2 or air + 5% CO2 for 16 h and treated with 5 mM H2O2 for 0–8 h. B: LDH release in LLC-PK1 cells pretreated with 2.2% sevoflurane/air + 5% CO2 or air + 5% CO2 for 16 h and treated with 5 mM H2O2 for 0–8 h. C: LDH release in LLC-PK1 cells pretreated with 2.2% sevoflurane/air + 5% CO2 or air + 5% CO2 for 16 h and treated with 1, 2, or 5 mM H2O2 for 8 h. D: LDH release in LLC-PK1 cells pretreated with 0.25–4.4% sevoflurane/air + 5% CO2 or air + 5% CO2 for 16 h and treated with 5 mM H2O2 for 4 h. E: LDH release in LLC-PK1 cells pretreated with 2.2% sevoflurane/air + 5% CO2 or air + 5% CO2 for 1–16 h and treated with 5 mM H2O2 for 4 h. Error bars represent SE. A-E: *P < 0.05 vs. H2O2 injury without sevoflurane pretreatment.

 
Following 16 h of 2.2% sevoflurane pretreatment, cells were exposed to 1, 2, or 5 mM H2O2 for 8 h at 37°C in a humidified 5% CO2 incubator. 2.2% Sevoflurane pretreatment significantly decreased the amount of total cellular LDH released at each dose of H2O2 (Fig. 1C; LDH released with 1, 2, or 5 mM H2O2 treatment = 13.1 ± 1.5%, n = 9, P < 0.05), 19.3 ± 1.9% (n = 9, P < 0.05), and 36.6 ± 0.8% (n = 6, P < 0.05) after sevoflurane treatment, respectively, vs. LDH released = 24.5 ± 2.1% (n = 6), 32.5 ± 3.9% (n = 6), and 52.5 ± 2.0% (n = 6) without sevoflurane treatment. To evaluate the dose-dependent protection of sevoflurane against H2O2-induced necrosis in LLC-PK1 cells, LLC-PK1 cells were pretreated with 0.55, 1.1, 2.2, or 4.4% sevoflurane for 16 h before 4 h of 5 mM H2O2. Significant reduction in total cellular LDH release was achieved with 0.25–4.4% sevoflurane pretreatment (Fig. 1D). To evaluate the pretreatment time course of sevoflurane-mediated protection against H2O2-induced necrosis in LLC-PK1 cells, sevoflurane pretreatment was done for 2, 4, 10, or 16 h before 4 h of 5 mM H2O2. Significant reduction in total cellular LDH release was achieved with 4, 10, or 16 h of sevoflurane pretreatment (Fig. 1E). In contrast, sevoflurane pretreatment for 1–2 h did not protect against H2O2-induced necrosis.

Sevoflurane treatment results in activation of prosurvival kinases ERK and Akt. 2.2% sevoflurane treatment increased phosphorylation of ERK1/2 and Akt within 1 h in HK-2 cells (Fig. 2, A and B) and LLC-PK1 cells (data not shown). ERK and Akt phosporylation peaked at 4 h and then returned to baseline after the 4-h time point (Fig. 2B). The band intensities for total ERK and Akt did not change with increased phosphorylation of these proteins (data not shown).


Figure 2
View larger version (28K):
[in this window]
[in a new window]
  		Fig. 2. A: representative immunoblots for phospho-ERK and phospho-Akt from HK-2 cells treated with 2.2% sevoflurane for 1–16 h. Representative blot of 6 experiments is shown. B: densitometric quantifications of relative band intensities (expressed as a ratio of phosphorylated over total forms) for pERK2 and pAKT (n = 6) in HK-2 cells. *P < 0.05 vs. 0 hour.

 
Sevoflurane-induced protection is abolished by inhibition of Akt or ERK. Pretreatment with wortmanin or with PD-98059 before sevoflurane treatment blocked sevoflurane-mediated protection against H2O2 in HK-2 cells (Fig. 3) as well as LLC-PK1 cells (data not shown). LDH released from cells treated only with wortmanin or PD-98059 was similar to vehicle-treated cells. Inhibition of ERK or Akt at the time of H2O2 injury (after 16-h sevoflurane pretreatment) failed to prevent sevoflurane-mediated protection against H2O2 injury (data not shown).


Figure 3
View larger version (32K):
[in this window]
[in a new window]
  		Fig. 3. Effects of inhibition of PI3K or MEK1 on sevoflurane-mediated HK-2 cell protection against H2O2 (5 mM for 4 h) necrosis. HK-2 cells were treated with 2.2% Sevo for 16 h (n = 5). Some cells were pretreated with wortmanin (Wort; n = 9) or PD-98059 (PD; n = 9) 30 min before sevoflurane treatment. *P < 0.05 vs. vehicle-treated group.

 
Quantitative accuracy of the RT-PCR technique. All PCR methods by definition involve amplification of an original target and are thus at risk of losing quantitative accuracy. Both the RNA input and cycle number of PCR gave a result that was within the range of a linear response. Total RNA was isolated from freshly isolated proximal tubules and the quantitative accuracy of the RT-PCR technique was first confirmed. RT-PCR reactions for ICAM-1 mRNA are shown as a representative study; however, tests for quantitative nature of RT-PCR technique were performed for all of the primers used in this study. The PCR cycle for each primer pair was optimized for linear increases in densitometric measurements with increasing PCR cycles from 14–22 (Fig. 4, left). The starting amount of RNA (0.25–1 µg) was also optimized for linear increase in densitometric measurements at an optimized cycle of PCR (Fig. 4, right).


Figure 4
View larger version (23K):
[in this window]
[in a new window]
  		Fig. 4. To confirm the quantitative nature of our RT-PCR technique for ICAM-1, we verified that band density increased linearly with the number of PCR cycles (left) and with the amount of starting RNA isolated from rat kidney proximal tubules (right; showing 18 PCR cycles).

 
Sevoflurane decreases proinflammatory mRNA expression in HK-2 cells. Concomitant sevoflurane treatment caused time (Fig. 5)- and dose-dependent (data not shown) attenuation of proinflammatory mRNA upregulation in response to TNF-{alpha}. Figure 5A shows representative gel images of RT-PCR results for TNF-{alpha}, ICAM-1, and MCP-1 in HK-2 cells after TNF-{alpha} treatment or after TNF-{alpha} plus sevoflurane (representative of 5 experiments). Figure 5B shows densitometric quantifications of relative band intensities from RT-PCR reactions for each indicated mRNA treated with TNF-{alpha} or with TNF-{alpha} plus 2.2% sevoflurane for 16 h. Treatment with TNF-{alpha} for 16 h increased TNF-{alpha}, ICAM-1, and MCP-1 mRNA expression in HK-2 cells by 2.0 ± 0.1 (n = 9)-, 1.7 ± 0.1 (n = 9)-, and 1.9 ± 0.3 (n = 5)-fold, respectively, and treatment with 2.2% sevoflurane reduced expression to 1.6 ± 0.1 (n = 9, P < 0.05)-, 1.2 ± 0.1 (n = 6, P < 0.05)-, and 1.0 ± 0.1 (n = 5, P < 0.05)-fold, respectively. Similarly, sevoflurane reduced expression of proinflammatory mRNA in response to H2O2 treatment (data not shown).


Figure 5
View larger version (20K):
[in this window]
[in a new window]
  		Fig. 5. A: representative gel images of semiquantitative RT-PCR results of proinflammatory markers ICAM-1, TNF-{alpha}, and MCP-1 from HK-2 cells treated with 10 ng/ml TNF-{alpha} or with 10 ng/ml TNF-{alpha} plus 2.2% sevoflurane for 2, 4, or 16 h. Representative image of 5 experiments is shown. B: densitometric quantifications of relative band intensities from RT-PCR reactions for each indicated mRNA compared with GAPDH band intensity treated with 10 ng/ml TNF-{alpha} or with 10 ng/ml TNF-{alpha} plus 2.2% sevoflurane for 16 h. *P < 0.05 vs. control. #P < 0.05 vs. TNF-{alpha}.

 
Protein expression of ICAM-1 is suppressed with sevoflurane in HK-2 cells. TNF-{alpha} (Fig. 6) or H2O2 (data not shown) treatment increased protein expression of ICAM-1 in HK-2 cells which was reduced by 2.2% sevoflurane for 16 h (n = 4) consistent with our result of sevoflurane's effects on ICAM-1 mRNA expression (Fig. 5B).


Figure 6
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 6. Representative immunoblot of ICAM-1 expression in HK-2 cells after 16 h of vehicle (Veh), 10 ng/ml TNF-{alpha} (TNF), 2.2% Sevo, or 10 ng/ml TNF-{alpha} + 2.2% Sevo. Representative blot of 4 experiments is shown.

 
Sevoflurane selectively increases HSP-70 mRNA and protein. As shown in Fig. 7, A and B, HSP-70 mRNA was significantly increased at 4, 8, or 16 h after sevoflurane treatment in HK-2 cells. HSP-70 protein expression also increased significantly after 1, 2, 4, 8, or 16 h of sevoflurane treatment in HK-2 cells (Fig. 7, C and D). In contrast, there was no significant upregulation of HSP-27, HO-1 (HSP-32), and HSP-90 mRNA or protein expression after sevoflurane treatment (Figs. 7, A-D). Upregulation of HSP-70 is not specific for sevoflurane as other inhalational anesthetics including isoflurane and halothane also upregulated HSP-70 mRNA and protein expression (data not shown). Similar selective upregulation of HSP-70 mRNA and protein occurred in LLC-PK1 cells after sevoflurane treatment (data not shown). Pretreatment with wortmanin or with PD-98059 blocked sevoflurane-mediated upregulation of HSP-70 protein (Fig. 7E). De novo gene transcription and protein synthesis are required for HSP-70 upregulation with sevoflurane treatment as actinomynocin D (an inhibitor of new gene transcription, 10 µg/ml, 30-min pretreatment before sevoflurane) and cycloheximide (an inhibitor of new protein synthesis, 10 µg/ml, 30-min pretreatment before sevoflurane), respectively, blocked HSP-70 upregulation (Fig. 7F).


Figure 7
View larger version (39K):
[in this window]
[in a new window]
  		Fig. 7. A: representative gel images of semiquantitative RT-PCR results of heat shock proteins (HSP)-32 (HO-1), -27, -70, and GAPDH from HK-2 cells treated with 2.2% sevoflurane for 0–16 h. Representative image of 6 experiments is shown. C: representative immunoblots of HSP-32, -27, and -70 from HK-2 cells treated with 2.2% sevoflurane for 0–16 h. Representative blot of 6 experiments is shown. B and D: densitometric quantifications of relative band intensities from RT-PCR reactions compared with GAPDH band intensity (B) and immunoblots (D). *P < 0.05 vs. 0 hour. E: increase in HSP-70 protein expression with sevoflurane is blocked with 50 µM PD-98059 (PD) or 100 nM Wort. A duplicate sample experiment is shown representative of 4 independent experiments. F: increase in HSP-70 protein expression with sevoflurane is blocked with 10 µg/ml actinomycin D (ActD) or with 10 µg/ml cycloheximide (CXM). A duplicate sample experiment is shown representative of 4 independent experiments.

 
Sevoflurane suppresses TNF-{alpha}-induced NF-{kappa}B and AP-1 translocation in HK-2 cells. TNF-{alpha} treatment for 16 h dose dependently increased nuclear translocation of NF-{kappa}B and AP-1 in HK-2 cells (Fig. 8, A and C). Exposure to 2.2% sevoflurane for 16 h during TNF-{alpha} treatment decreased NF-{kappa}B (Fig. 8, A and B) and AP-1 translocation (Fig. 8, C and D). Figure 8, A and C, shows representative blots of NF-{kappa}B and AP-1 EMSA after TNF-{alpha} treatment or after TNF-{alpha} plus sevoflurane for 16 h (representative of 5 experiments). Figure 8, B and D, shows densitometric quantifications of relative band intensities from NF-{kappa}B as well as AP-1 EMSA TNF-{alpha} treatment or after TNF-{alpha} plus sevoflurane for 16 h. Treatment with 10 ng/ml TNF-{alpha} for 16 h increased nuclear translocation of NF-{kappa}B (1.9 ± 0.2-fold, n = 8, P < 0.05 vs. saline-treated group) and AP-1 (1.7 ± 0.2-fold, n = 5, P < 0.05 vs. saline-treated group) and these increases in proinflammatory transcription factors were significantly attenuated by 2.2% sevoflurane (NF-{kappa}B = 1.4 ± 0.1-fold, n = 9, P < 0.05, and AP-1 = 1.2 ± 0.1, n = 5, P < 0.05; Fig. 8, B and D). Figure 9 shows a dose-dependent reduction of TNF-{alpha}-induced NF-{kappa}B translocation with increasing concentrations of sevoflurane at 0.28, 0.55, 1.1, and 2.2% for 16 h thus further confirming the direct inhibitory effect of sevoflurane on NF-{kappa}B (representative of 6 experiments). Similar dose-dependent inhibition of AP-1 translocation by sevoflurane was observed (data not shown).


Figure 8
View larger version (57K):
[in this window]
[in a new window]
  		Fig. 8. Representative gel image of NF-{kappa}B (A) and AP-1 (C) electrophoretic mobility shift assay (EMSA) of nuclear extracts from HK-2 cells treated with increasing doses of TNF-{alpha} (0.1–10 ng/ml) in 95% air-5% CO2 or in 2.2% sevoflurane. Hela nuclear extracts were used as a positive control. Representative images of 5 experiments are shown. B and D: densitometric quantifications of relative band intensities from NF-{kappa}B (n = 9) and AP-1 EMSA (n = 5). *P < 0.05 vs. TNF-{alpha}.

 

Figure 9
View larger version (51K):
[in this window]
[in a new window]
  		Fig. 9. Representative gel image of NF-{kappa}B EMSA of nuclear extracts from HK-2 cells treated with increasing doses of sevoflurane (0–2.2% for 16 h). Representative image of 6 experiments is shown.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The major findings of the current study are that clinically relevant concentrations (0.25–2 MAC) of sevoflurane reduce inflammation as well as necrosis in human and porcine renal tubule (HK-2 and LLC-PK1) cells. In addition, sevoflurane reduces proinflammatory transcription factors NF-{kappa}B and AP-1 as well as proinflammatory mRNA and protein expression. Reduction in necrosis and inflammation with sevoflurane were associated with activation of prosurvival kinases ERK and Akt (PKB) as well as selective increased synthesis of HSP-70 dependent on ERK and Akt activation.

We demonstrated recently that volatile anesthetics reduced necrosis and inflammation in rats after renal IR injury in vivo (29). Renal IR under sevoflurane anesthesia resulted in drastic improvements in renal function, improved preservation of renal proximal tubular architecture, reduced necrosis, and resulted in near-complete inhibition of neutrophil influx. However, with in vivo studies, it is difficult to determine whether the protective effects were due to direct renal tubular effects and/or due to effects on leukocyte/neutrophil activation and infiltration. Therefore, in the current study, we questioned whether a volatile anesthetic produced direct anti-inflammatory and protective effects on renal proximal tubule cells in culture. We focused on cultures of proximal tubules as these cells are the primary site of injury in renal IR (30, 61). This region is marginally oxygenated under normal physiological conditions with a high basal metabolic demand (8, 30). Therefore, with IR injury, proximal tubules in the outer medullary zone suffer the most damage. Our study shows that sevoflurane had direct anti-inflammatory as well as direct antinecrotic effects in in vitro cultures of proximal tubule cells.

In this study, we injured HK-2 cells with H2O2 to produce necrosis. We demonstrate that H2O2 causes dose-dependent necrosis in both HK-2 and LLC-PK1 cells (Fig. 1). Oxygen free radical generation with resultant oxidant tissue stress is a major cause of renal reperfusion injury (12, 42). During reperfusion after ischemia, reactive oxygen species, such as superoxide anion, hydroxyl radical, and H2O2, are generated. These reactive oxygen species cause lipid peroxidation of the renal cell membrane with resultant intracellular calcium overload and subsequent necrotic cell death (42, 52, 53). We demonstrate in this study that as we observed in vivo, sevoflurane treatment protects against oxidant-mediated injury in human renal proximal tubule cells. Our data demonstrate that the antinecrotic effect of sevoflurane is not specific to human cells as LLC-PK1 cells are protected against necrosis as well. We again demonstrate that induction of necrosis in in vitro immortalized proximal tubule cells requires high doses of H2O2 (1–5 mM) as we reported previously (26).

A typical general anesthetic case requires ~1 MAC defined as the percent inhalational agent required to stop 50% of subjects from moving in response to a surgical stimulus. We demonstrate that clinically relevant concentrations of sevoflurane (0.25–2 MAC) produced concentration-dependent and significant protection against proximal tubule necrosis. Moreover, we show that 4-h pretreatment with 1 MAC (2.2%) sevoflurane produced significant protection against necrosis. Our study provides evidence that pretreatment with sevoflurane results in a significant change in the cultured renal tubule cells that persists for several hours following clearance of the anesthetic. This raises the exciting possibility that beneficial anesthetic effects persist after clearance of the agent due to induced changes in intracellular signaling in proximal tubules. Taken together, our findings may have clinical significance for patients undergoing general anesthesia in the operating room.

We demonstrate in this study for the first time that sevoflurane pretreatment is associated with increased phosphorylation of Akt and ERK MAPK in renal tubule cells. Sevoflurane-related increases in phosphorylation of Akt and ERK have been reported in hippocampal slice cultures (11), cardiomyocytes (57), and vascular smooth muscle cells (70). ERK MAPK and/or Akt activation reduce necrosis after IR injury in several organs (7, 38, 58). For example, ERK activation mediates ischemic preconditioning in the heart (35, 36) and Akt activation improves outcome after IR injury in the heart (58). In addition, isoflurane may protect against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase and Akt signal transduction (6, 58). However, in renal IR injury, the role of Akt and ERK in proximal tubule cell cytoprotection is not as clear.

Interestingly, 1- to 2-h treatment with sevoflurane failed to significantly protect either HK-2 or LLC-PK1 cells against necrosis. Only 4- to 16-h pretreatments induced significant protection suggesting that newly synthesized cytoprotective protein(s) (e.g., HSP-70) is (are) involved in protection. HSP-70 upregulation begins after ~4 h of sevoflurane pretreatment (Fig. 6) and at least 4-h sevoflurane pretreatment is required for cytoprotection to occur (Fig. 1E). However, we showed that ERK and Akt activation occurred within 1 h of sevoflurane treatment and peaked at 4 h before returning to baseline at 16 h. We also showed that pharmacological inhibition of Akt or ERK phosphorylation blocked sevoflurane-mediated protection against necrosis in HK-2 cells and LLC-PK1 cells. Moreover, activation of ERK and Akt is responsible for sevoflurane-mediated upregulation of HSP-70 as inhibition of ERK or Akt phosphorylation prevented the upregulation of HSP-70. Therefore, we conclude that early (1–4 h) activation of ERK and Akt pathways participates in mediating sevoflurane's antinecrotic effects by mediating the upregulation of HSP-70. The early increase in pERK and pAkt induced by sevoflurane is both necessary and sufficient to account for the protection measured at the later (16 h) time point. This conclusion is further supported by the fact that inhibition of ERK and Akt after sevoflurane (16 h) treatment failed to prevent sevoflurane-mediated protection against H2O2 injury.

In our previous in vivo study, 1-h pretreatment with volatile anesthetic failed to protect renal function. Volatile anesthetics needed to be administered during ischemia and for 3 h after reperfusion suggesting that brief exposure to volatile anesthetics is not sufficient to induce renal protection. Our in vitro as well as in vivo data suggest that new protein synthesis (e.g., HSP-70) perhaps subsequent to ERK and/or Akt activation (phosphorylation) might be required for sevoflurane-mediated protection in renal cells.

In this study, we used two independent cell lines of renal tubules (HK-2 and LLC-PK1) to confirm that the renal tubular effects of sevoflurane do not occur in a single cell line. HK-2 cells are immortalized adult human proximal tubular cells transfected with E6/E7 genes of the human papilloma virus (HPV16) (51). Transfection with HPV16 has been shown to immortalize epithelial cells of diverse origin without significantly altering their phenotype or function. HK-2 cells have been shown to retain the phenotypic expression and functional characteristics of human proximal tubules (46, 51). Extensive studies have used HK-2 cells to study in vitro renal physiology and pathology (19, 20, 69). LLC-PK1 cells are transformed, stable porcine renal tubule cell line with similar transport characteristic of proximal tubule cells (16, 44).

In renal IR injury, sublethal injury is amplified by the inflammatory cascade that occurs during the reperfusion period (23, 24, 50). The inflammatory response is initiated and elaborated by cytokines (e.g., TNF-{alpha}), chemoattractive chemokines (e.g., IL-8, MCP-1, MIP-2), and the expression of adhesion molecules (e.g., ICAM-1, selectins) (3, 9, 10). Recent evidence indicates that elaboration of these adhesion molecules not only occur in nonrenal cells (e.g., endothelial cells, dendritic cells) but also in renal proximal tubules cells. We previously showed in vivo that mRNA for proinflammatory ICAM-1, TNF-{alpha}, and chemokines (MCP-1, MIP-2, IL-8, and IP-10) in rat renal cortices is upregulated 16 h after IR injury. However, in vivo, it is difficult to determine the exact source of this chemokine and cytokine generation in the kidney (e.g, proximal tubules, endothelial cells). We now show that renal proximal tubule cells can directly upregulate cytokine and chemokine mRNA in response to TNF-{alpha}. We also showed recently that volatile anesthetics reduce inflammatory changes after renal IR injury in vivo. Again, with in vivo studies, it is impossible to determine whether the anti-inflammatory response is direct (e.g., renal proximal tubule cells are targeted), indirect (e.g., endothelial cells, dendritic cells are targeted), or both. We show in this study for the first time that sevoflurane has direct anti-inflammatory effects in proximal tubules cells in culture. Attenuation of the expression of these cytokines and chemokines from proximal tubules by sevoflurane may contribute to the reduction in renal inflammatory injury after IR.

Nuclear translocation of transcription factors such as NF-{kappa}B or AP-1 plays an important role in propagating the inflammatory process. In the nucleus, these transcription factors bind to specific DNA motifs and regulate transcription of target genes including TNF-{alpha}, ICAM-1, as well as several key chemokines involved in inflammatory renal tubular damage (MCP-1, MIP-2, and IP-10) (2, 21, 49). We showed in our in vivo study that renal cortical NF-{kappa}B nuclear translocation is attenuated by volatile anesthetic treatment. We show in this study that increased NF-{kappa}B and AP-1 nuclear translocation in response to a proinflammatory stimulus TNF-{alpha} is directly and significantly reduced in HK-2 cells following sevoflurane treatment. Blocking NF-{kappa}B or AP-1 transcription attenuates inflammation and reduces cell death in many pathophysiological states including sepsis or IR injury (34, 59, 60). Therefore, the direct reduction of proinflammatory transcription factor activation by sevoflurane may contribute to renal protection.

In this study, we sought to examine other mechanisms of sevoflurane-mediated anti-inflammatory and antinecrotic effects with in vitro approaches. Volatile anesthetics cause upregulation of HSP-70 and -32 in the liver (15, 64). However, it is unclear whether volatile anesthetics modulate HSP expression in the kidney. We focused on three well-known cytoprotective HSPs; HSP-27, HO-1 (HSP-32), and HSP-70 of the diverse family members of heat shock proteins. Our data demonstrate that sevoflurane selectively upregulated mRNA and protein expression of inducible HSP-70 without affecting the expression of HSP-27 or HO-1.

The 70-kDa HSP-70 belongs to a family of highly conserved molecular chaperones that regulate protein folding and subsequent protein structure preservation during normal and stress conditions (5). In addition to promoting protein folding, HSP-70 is a well-known cytoprotective protein. In cultured renal epithelial cells, protection from adenosine 5'-triphosphate (ATP) depletion or heat stress is correlated with HSP-70 levels (39, 40, 62, 63). HSP-70 expression is inversely correlated with myocardial infarct size in rats (17, 18) and overexpression of HSP-70 in mice protects against cardiac ischemia (45). Induction of HSP-70 expression leads to increased resistance against in vivo renal IR injury (55, 65, 66). We demonstrate for the first time that sevoflurane increases HSP-70 mRNA and protein expression in HK-2 cells and LLC-PK1 cells. In addition to activating ERK and Akt, sevoflurane may protect renal proximal tubules against necrosis and inflammation by a HSP-70-mediated mechanism. We demonstrated that inhibition of ERK and Akt phosphorylation blocked both sevoflurane-mediated protection against oxidant-induced necrosis and upregulation of HSP-70. These results support the hypothesis that HSP-70 plays an integral role in sevoflurane-mediated protection against necrosis.

In this study, only the direct effects of sevoflurane on renal proximal tubule cell survival were studied. The effects of sevoflurane on leukocyte infiltration after renal IR may be another potential renal protective mechanism of sevoflurane. A potential limitation in the interpretation of this study is that immortalized renal tubule cells are used instead of primary cultures.

The direct signaling mechanism(s) of sevoflurane-mediated activation of ERK and Akt remains to be determined. However, based on the studies performed in other organs (e.g., heart), we may speculate several possible mechanisms. Volatile anesthetics directly interact with the mitochondrial electron transport chain (14, 22) which may augment the release of reactive oxygen species. Indeed, exposure to volatile anesthetics has been shown to generate minute quantities of reactive oxygen species in the heart (4, 41). Although large quantities of reactive oxygen species cause direct cellular injury contributing to the pathogenesis of IR injury, a small amount of reactive oxygen species triggers activation of several kinases including ERK and Akt (4). In addition, volatile anesthetics may activate several G protein-coupled receptors including A1 adenosine receptors as selective blockade of these receptors abolished the cardiac protective effects of volatile anesthetic-mediated preconditioning (13, 25, 68). Volatile anesthetics may also bind and directly activate Gi proteins as pertussis toxin prevented volatile anesthetic-mediated cardiac protection in dogs (56). Therefore, volatile anesthetics may trigger the phosphorylation of ERK and Akt via activation of Gi-coupled receptor-mediated pathways.

In conclusion, our study shows that sevoflurane directly reduced necrosis and inflammation in proximal tubules in vitro via mechanisms involving reduction of proinflammatory transcription factors (NF-{kappa}B and AP-1) and reduction in proinflammatory mRNAs. Sevoflurane also activated prosurvival kinases ERK and Akt and upregulation of HSP-70 (Fig. 10). Further elucidation of the signaling pathways of sevoflurane-mediated activation of cytoprotective pathways may lead to effective therapies against renal IR injury and acute renal failure.


Figure 10
View larger version (11K):
[in this window]
[in a new window]
  		Fig. 10. Proposed signaling pathways of sevoflurane-mediated renal tubular protection against inflammation and necrosis. Sevoflurane treatment results in phosphorylation of ERK and Akt as well as upregulation of HSP-70. Sevoflurane treatment also leads to reduction in nuclear translocation of NF-{kappa}B. It remains to be determined whether cross-talk exists between ERK and Akt signaling pathways.

 

   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was funded by the intramural grant support from the Department of Anesthesiology, Columbia University College of Physicians and Surgeons and by Grant R01-GM-067081.


   FOOTNOTES
 

Address for reprint requests and other correspondence: H. Thomas Lee, Dept. of Anesthesiology, Anesthesiology Research Laboratories, Columbia Univ., P&S Box 46 (PH-5), 630 West 168th St., New York, NY 10032-3784 (e-mail: tl128{at}columbia.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Aronson S and Blumenthal R. Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardiothorac Vasc Anesth 17: 117–130, 1998.
  2. Baud V and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11: 372–377, 2001.[CrossRef][Web of Science][Medline]
  3. Beauchamp P, Richard V, Tamion F, Lallemand F, Lebreton JP, Vaudry H, Daveau M, and Thuillez C. Protective effects of preconditioning in cultured rat endothelial cells: effects on neutrophil adhesion and expression of ICAM-1 after anoxia and reoxygenation. Circulation 100: 541–546, 1999.[Abstract/Free Full Text]
  4. Bienengraeber MW, Weihrauch D, Kersten JR, Pagel PS, and Warltier DC. Cardioprotection by volatile anesthetics. Vascul Pharmacol 42: 243–252, 2005.[CrossRef][Web of Science][Medline]
  5. Boorstein WR, Ziegelhoffer T, and Craig EA. Molecular evolution of the HSP70 multigene family. J Mol Evol 38: 1–17, 1994.[Web of Science][Medline]
  6. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, and Warltier DC. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 102: 102–109, 2005.[CrossRef][Web of Science][Medline]
  7. Di Mari JF, Davis R, and Safirstein RL. MAPK activation determines renal epithelial cell survival during oxidative injury. Am J Physiol Renal Physiol 277: F195–F203, 1999.[Abstract/Free Full Text]
  8. Dinour D, Agmon Y, and Brezis M. Adenosine: an emerging role in the control of renal medullary oxygenation? Exp Nephrol 1: 152–157, 1993.[Web of Science][Medline]
  9. Donnahoo KK, Meldrum DR, Shenkar R, Chung CS, Abraham E, and Harken AH. Early renal ischemia, with or without reperfusion, activates NF{kappa}B and increases TNF-{alpha} bioactivity in the kidney. J Urol 163: 1328–1332, 2000.[CrossRef][Web of Science][Medline]
  10. Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, and Meldrum DR. Early kidney TNF-{alpha} expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol Regul Integr Comp Physiol 277: R922–R929, 1999.[Abstract/Free Full Text]
  11. Gray JJ, Bickler PE, Fahlman CS, Zhan X, and Schuyler JA. Isoflurane neuroprotection in hypoxic hippocampal slice cultures involves increases in intracellular Ca2+ and mitogen-activated protein kinases. Anesthesiology 102: 606–615, 2005.[CrossRef][Web of Science][Medline]
  12. Greene EL and Paller MS. Oxygen free radicals in acute renal failure. Miner Electrolyte Metab 17: 124–132, 1991.[Web of Science][Medline]
  13. Hanouz JL, Yvon A, Massetti M, Lepage O, Babatasi G, Khayat A, Bricard H, and Gerard JL. Mechanisms of desflurane-induced preconditioning in isolated human right atria in vitro. Anesthesiology 97: 33–41, 2002.[CrossRef][Web of Science][Medline]
  14. Hartman PS, Ishii N, Kayser EB, Morgan PG, and Sedensky MM. Mitochondrial mutations differentially affect aging, mutability and anesthetic sensitivity in Caenorhabditis elegans. Mech Ageing Dev 122: 1187–1201, 2001.[CrossRef][Web of Science][Medline]
  15. Hoetzel A, Geiger S, Loop T, Welle A, Schmidt R, Humar M, Pahl HL, Geiger KK, and Pannen BH. Differential effects of volatile anesthetics on hepatic heme oxygenase-1 expression in the rat. Anesthesiology 97: 1318–1321, 2002.[CrossRef][Web of Science][Medline]
  16. Hull RN, Cherry WR, and Weaver GW. The origin and characteristics of a pig kidney cell strain, LLC-PK. In Vitro 12: 670–677, 1976.[Web of Science][Medline]
  17. Hutter JJ, Mestril R, Tam EK, Sievers RE, Dillmann WH, and Wolfe CL. Overexpression of heat shock protein 72 in transgenic mice decreases infarct size in vivo. Circulation 94: 1408–1411, 1996.[Abstract/Free Full Text]
  18. Hutter MM, Sievers RE, Barbosa V, and Wolfe CL. Heat-shock protein induction in rat hearts. A direct correlation between the amount of heat-shock protein induced and the degree of myocardial protection. Circulation 89: 355–360, 1994.[Abstract/Free Full Text]
  19. Iwata M, Herrington J, and Zager RA. Protein synthesis inhibition induces cytoresistance in cultured human proximal tubular (HK-2) cells. Am J Physiol Renal Fluid Electrolyte Physiol 268: F1154–F1163, 1995.[Abstract/Free Full Text]
  20. Iwata M, Myerson D, Torok-Storb B, and Zager RA. An evaluation of renal tubular DNA laddering in response to oxygen deprivation and oxidant injury. J Am Soc Nephrol 5: 1307–1313, 1994.[Abstract]
  21. Karin M, Takahashi T, Kapahi P, Delhase M, Chen Y, Makris C, Rothwarf D, Baud V, Natoli G, Guido F, and Li NX. Oxidative stress and gene expression: the AP-1 and NF-{kappa}B connections. Biofactors 15: 87–89, 2001.[Web of Science][Medline]
  22. Kayser EB, Morgan PG, and Sedensky MM. GAS-1: a mitochondrial protein controls sensitivity to volatile anesthetics in the nematode Caenorhabditis elegans. Anesthesiology 90: 545–554, 1999.[CrossRef][Web of Science][Medline]
  23. Kelly KJ, Williams WW Jr, Colvin RB, and Bonventre JV. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 91: 812–816, 1994.[Abstract/Free Full Text]
  24. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, and Bonventre JV. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 97: 1056–1063, 1996.[Web of Science][Medline]
  25. Kersten JR, Orth KG, Pagel PS, Mei DA, Gross GJ, and Warltier DC. Role of adenosine in isoflurane-induced cardioprotection. Anesthesiology 86: 1128–1139, 1997.[CrossRef][Web of Science][Medline]
  26. Lee HT and Emala CW. Adenosine attenuates oxidant injury in human kidney proximal tubular cells via A1 and A2a adenosine receptor activation. Am J Physiol Renal Physiol 282: F844–F852, 2002.[Abstract/Free Full Text]
  27. Lee HT and Emala CW. Characterization of adenosine receptors in human kidney proximal tubule (HK-2) cells. Exp Nephrol 10: 383–392, 2002.[CrossRef][Web of Science][Medline]
  28. Lee HT, Ota-Setlik A, Fu Y, Nasr SH, and Emala CW. Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology 101: 1313–1324, 2004.[Web of Science][Medline]
  29. Lieberthal W and Nigam SK. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol Renal Physiol 275: F623–F631, 1998.[Abstract/Free Full Text]
  30. Lovis C, Mach F, Donati YR, Bonventre JV, and Polla BS. Heat shock proteins and the kidney. Ren Fail 16: 179–192, 1994.[Web of Science][Medline]
  31. Maher ER, Robinson KN, Scoble JE, Farrimond JG, Browne DR, Sweeny P, and Morehead JF. Prognosis of critically ill patients with acute renal failure: APACHE II score and other predictive factors. QJM 72: 857–866, 1989.[Abstract/Free Full Text]
  32. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, and Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 128: 194–203, 1998.[Abstract/Free Full Text]
  33. Matsuda N, Hattori Y, Jesmin S, and Gando S. Nuclear factor-{kappa}B decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 67: 1018–1025, 2005.[Abstract/Free Full Text]
  34. Maulik N, Watanabe M, Zu YL, Huang CK, Cordis GA, Schley JA, and Das DK. Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts. FEBS Lett 396: 233–237, 1996.[CrossRef][Web of Science][Medline]
  35. Maulik N, Yoshida T, Zu YL, Sato M, Banerjee A, and Das DK. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol Heart Circ Physiol 275: H1857–H1864, 1998.[Abstract/Free Full Text]
  36. McCarthy JT. Prognosis of patients with acute renal failure in the intensive care unit: a tail of two eras. Mayo Clin Proc 71: 117–126, 1996.[Abstract]
  37. Mearow KM, Dodge ME, Rahimtula M, and Yegappan C. Stress-mediated signaling in PC12 cells–the role of the small heat shock protein, Hsp27, and Akt in protecting cells from heat stress and nerve growth factor withdrawal. J Neurochem 83: 452–462, 2002.[CrossRef][Web of Science][Medline]
  38. Nissim I, Hardy M, Pleasure J, Nissim I, and States B. A mechanism of glycine and alanine cytoprotective action: stimulation of stress-induced HSP70 mRNA. Kidney Int 42: 775–782, 1992.[Web of Science][Medline]
  39. Nissim I, States B, Hardy M, Pleasure J, and Nissim I. Effect of glutamine on heat-shock-induced mRNA and stress proteins. J Cell Physiol 157: 313–318, 1993.[CrossRef][Web of Science][Medline]
  40. Novalija E, Varadarajan SG, Camara AK, An J, Chen Q, Riess ML, Hogg N, and Stowe DF. Anesthetic preconditioning: triggering role of reactive oxygen and nitrogen species in isolated hearts. Am J Physiol Heart Circ Physiol 283: H44–H52, 2002.[Abstract/Free Full Text]
  41. Paller MS and Neumann TV. Reactive oxygen species and rat renal epithelial cells during hypoxia and reoxygenation. Kidney Int 40: 1041–1049, 1991.[Web of Science][Medline]
  42. Park KM, Chen A, and Bonventre JV. Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem 276: 11870–11876, 2001.[Abstract/Free Full Text]
  43. Perantoni A and Berman JJ. Properties of Wilms' tumor line (TuWi) and pig kidney line (LLC-PK1) typical of normal kidney tubular epithelium. In Vitro 15: 446–454, 1979.[Web of Science][Medline]
  44. Plumier JC, Ross BM, Currie RW, Angelidis CE, Kazlaris H, Kollias G, and Pagoulatos GN. Transgenic mice expressing the human heat shock protein 70 have improved postischemic myocardial recovery. J Clin Invest 95: 1854–1860, 1995.[Web of Science][Medline]
  45. Racusen LC, Monteil C, Sgrignoli A, Lucskay M, Marouillat S, Rhim JG, and Morin JP. Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 129: 318–329, 1997.[CrossRef][Web of Science][Medline]
  46. Ramesh G and Reeves WB. TNF-{alpha} mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110: 835–842, 2002.[CrossRef][Web of Science][Medline]
  47. Ramesh G and Reeves WB. Inflammatory cytokines in acute renal failure. Kidney Int Suppl 91: S56–S61, 2004.[Medline]
  48. Rangan GK, Wang Y, Tay YC, and Harris DC. Inhibition of NF{kappa}B activation with antioxidants is correlated with reduced cytokine transcription in PTC. Am J Physiol Renal Physiol 277: F779–F789, 1999.[Abstract/Free Full Text]
  49. Rovin BH and Phan LT. Chemotactic factors and renal inflammation. Am J Kidney Dis 31: 1065–1084, 1998.[Web of Science][Medline]
  50. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, and Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 45: 48–57, 1994.[Web of Science][Medline]
  51. Salahudeen AK. Role of lipid peroxidation in H2O2-induced renal epithelial (LLC-PK1) cell injury. Am J Physiol Renal Fluid Electrolyte Physiol 268: F30–F38, 1995.[Abstract/Free Full Text]
  52. Sheridan AM, Fitzpatrick S, Wang C, Wheeler DC, and Lieberthal W. Lipid peroxidation contributes to hydrogen peroxide-induced cytotoxicity in renal epithelial cells. Kidney Int 49: 88–93, 1996.[Web of Science][Medline]
  53. Star RA. Treatment of acute renal failure. Kidney Int 54: 1817–1831, 1998.[CrossRef][Web of Science][Medline]
  54. Suzuki S, Maruyama S, Sato W, Morita Y, Sato F, Miki Y, Kato S, Katsuno M, Sobue G, Yuzawa Y, and Matsuo S. Geranylgeranylacetone ameliorates ischemic acute renal failure via induction of Hsp70. Kidney Int 67: 2210–2220, 2005.[CrossRef][Web of Science][Medline]
  55. Toller WG, Kersten JR, Gross ER, Pagel PS, and Warltier DC. Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins. Anesthesiology 92: 1400–1407, 2000.[CrossRef][Web of Science][Medline]
  56. Toma O, Weber NC, Wolter JI, Obal D, Preckel B, and Schlack W. Desflurane preconditioning induces time-dependent activation of protein kinase C epsilon and extracellular signal-regulated kinase 1 and 2 in the rat heart in vivo. Anesthesiology 101: 1372–1380, 2004.[CrossRef][Web of Science][Medline]
  57. Tsang A, Hausenloy DJ, Mocanu MM, and Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230–232, 2004.[Abstract/Free Full Text]
  58. Ueno T, Sawa Y, Kitagawa-Sakakida S, Nishimura M, Morishita R, Kaneda Y, Kohmura E, Yoshimine T, and Matsuda H. Nuclear factor-{kappa}B decoy attenuates neuronal damage after global brain ischemia: a future strategy for brain protection during circulatory arrest. J Thorac Cardiovasc Surg 122: 720–727, 2001.[Abstract/Free Full Text]
  59. Valen G, Yan ZQ, and Hansson GK. Nuclear factor {kappa}B and the heart. J Am Coll Cardiol 38: 307–314, 2001.[Abstract/Free Full Text]
  60. Venkatachalam MA, Bernard DB, Donohoe JF, and Levinsky NG. Ischemic damage and repair in the rat proximal tubule: differences among the S1, S2, and S3 segments. Kidney Int 14: 31–49, 1978.[Web of Science][Medline]
  61. Wang YH and Borkan SC. Prior heat stress enhances survival of renal epithelial cells after ATP depletion. Am J Physiol Renal Fluid Electrolyte Physiol 270: F1057–F1065, 1996.[Abstract/Free Full Text]
  62. Wang YH, Knowlton AA, Li FH, and Borkan SC. Hsp72 expression enhances survival in adenosine triphosphate-depleted renal epithelial cells. Cell Stress Chaperones 7: 137–145, 2002.[CrossRef][Web of Science][Medline]
  63. Yamasaki A, Takahashi T, Suzuki T, Fujiwara T, Hirakawa M, Ohmori E, and Akagi R. Differential effects of isoflurane and halothane on the induction of heat shock proteins. Biochem Pharmacol 62: 375–382, 2001.[CrossRef][Web of Science][Medline]
  64. Yang CW, Ahn HJ, Han HJ, Kim WY, Li C, Shin MJ, Kim SK, Park JH, Kim YS, Moon IS, and Bang BK. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. Transplantation 72: 1753–1759, 2001.[CrossRef][Web of Science][Medline]
  65. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, Sun BK, Kim YS, Kim J, Chang YS, and Bang BK. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17: 1754–1755, 2003.[Abstract/Free Full Text]
  66. Yvon A, Hanouz JL, Haelewyn B, Terrien X, Massetti M, Babatasi G, Khayat A, Ducouret P, Bricard H, and Gerard JL. Mechanisms of sevoflurane-induced myocardial preconditioning in isolated human right atria in vitro. Anesthesiology 99: 27–33, 2003.[CrossRef][Web of Science][Medline]
  67. Zager RA, Burkhart KM, and Conrad DS. Isoflurane alters proximal tubular cell susceptibility to toxic and hypoxic forms of attack. Kidney Int 55: 148–159, 1999.[CrossRef][Web of Science][Medline]
  68. Zhong L and Su JY. Isoflurane activates PKC and Ca2+-calmodulin-dependent protein kinase II via MAP kinase signaling in cultured vascular smooth muscle cells. Anesthesiology 96: 148–154, 2002.[Web of Science][Medline]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
H. T. Lee, S. W. C. Chen, T. C. Doetschman, C. Deng, V. D. D'Agati, and M. Kim
Sevoflurane protects against renal ischemia and reperfusion injury in mice via the transforming growth factor-{beta}1 pathway
Am J Physiol Renal Physiol, July 1, 2008; 295(1): F128 - F136.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
H. T. Lee, M. Kim, J. H. Song, S. W. C. Chen, G. Gubitosa, and C. W. Emala
Sevoflurane-mediated TGF-{beta}1 signaling in renal proximal tubule cells
Am J Physiol Renal Physiol, February 1, 2008; 294(2): F371 - F378.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. Kim, M. Kim, N. Kim, V. D. D'Agati, C. W. Emala Sr, and H. T. Lee
Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1-phosphate-dependent pathways
Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1827 - F1835.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
H. T. Lee, M. Kim, M. Kim, N. Kim, F. T. Billings IV, V. D. D'Agati, and C. W. Emala Sr.
Isoflurane protects against renal ischemia and reperfusion injury and modulates leukocyte infiltration in mice
Am J Physiol Renal Physiol, September 1, 2007; 293(3): F713 - F722.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/1/F67    most recent
00412.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, H. T.
Right arrow Articles by Emala, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, H. T.
Right arrow Articles by Emala, C. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.